Alliance Healthcare Group Ltd – Innovative healthcare provider October 28, 2021 1142

  • Revenue grew at CAGR of 11.1% from FY18 to FY21. The new business segment, mobile and digital healthcare services, contributed a full year’s revenue in FY21.
  • Number of companies covered under Managed Healthcare Solutions grew at CAGR of 22.3% from 2016 to 2020.
  • Alliance Healthcare has been maintaining its dividend payout ratio of 30% since listing in 2019

 

Company Background

Established in 1994, Alliance Healthcare is a reliable medical brand with both in-house and GP specialist clinics, and specialises in corporate health solutions. They are also a wholesale pharmaceutical company facilitating timely access of medications to the region, and a progressive healthcare company making quality medical care within reach through mobile and home care service.

Key Highlights

  1. Revenue grew at CAGR of 11.1% from FY18 to FY21. AHG derives most of its revenue from rendering of services, including GP clinic and specialist care services and sale of pharmaceutical products. With 17 GP clinics and five specialist clinics across Singapore, AHG is able to serve customers island wide. The new business segment, mobile and digital healthcare services contributed a full year’s revenue in FY21.
  2. Companies covered under Managed Healthcare Solutions growing. The number of companies covered grew from 1,478 in 2016 to 3,309 in 2020, as at 31 December 2020, at CAGR of 22.3%. With the Alliance Healthcare Network which covers more than 1,000 medical services providers, including GP, specialist, dental, physiotherapy, companies are able to benefit from its wide range of services for their employees.
  3. Expand product offerings. Since April 2020, AHG launched HeyAlly, its digital and telemedicine platform. The app provides users access to services such as telemedicine, second opinion and comes with an online store offering a range of healthcare and wellness solutions, like health screening and vaccination. In January 2020, AHG acquired a 55% stake in Jaga-Me, a mobile healthcare company. The app allows users to schedule and pay for clinical services, medical equipment and consumables delivered to them. Jaga-Me deploys a network of over five hundred licensed healthcare professionals. The app was also one of the medical providers appointed by the Ministry of Health to administer home vaccinations and home Covid-19 swab tests.
  4. First distribution of dividends in FY20. Newly listed on SGX Catalist since 2019, AHG recommended a dividend payout ratio of 30%. Since then, AHG has declared dividends of 0.34 and 0.23 Scts for FY20 and FY21 respectively, representing payout ratios of 30% and 31% respectively. This reflects AHG’s confidence in the strength and quality of the businesses.
  5. Anticipated re-opening of borders should benefit. As Singapore’s borders are expected to gradually reopen, AHG is cautiously optimistic that it will positively impact its businesses, particularly the managed healthcare solutions and GP clinics services segments, with more clinic visits.
  6. Net cash position. AHG has maintained its net cash position since FY19, at S$9.9mn in FY21. At 28% of its market cap, its balance sheet remains healthy.

REVENUE

Managed healthcare solutions. Under Alliance MediNet, AHG offers medical services to employees of corporations and insured members of policy holders. Through arrangements with 8 insurers, AHG serves almost 3,700 corporations through their network of over 1,000 medical services providers within the Alliance Healthcare network. This includes GP and specialist clinics, private and public hospitals, etc. AHG collects an admin fee for every claim.

GP clinic services. AHG operates GP clinics under the name of “My Family Clinic”, providing medical services to individuals, with 16 clinics situated all around Singapore.

Specialist care services. AHG provides medical diagnosis and medical or surgical treatments of colorectal, ENT and orthopaedic conditions. With the newest addition of the orthopaedic clinic which commenced operations in December 2018, there are a total of five specialist clinics under AHG’s belt.

Pharmaceutical services. AHG engages in wholesale distribution of pharmaceutical products to hospitals, pharmacies and clinics in Singapore and other overseas markets.

Mobile and Digital Health Services. AHG provides quality medical care within reach through mobile and home care services. In April 2020, AHG launched HeyAlly, which is a digital health and telemedicine platform, revenue is earned from the provision of on-demand medical advice through tele-consultation. Jaga-Me Pte Ltd is a mobile health company, which AHG acquired 55% interest in January 2020. Through this app, patients could get access to healthcare services at the comfort of their homes or workplace, through the digital platform. Revenue is derived from the provision of home care nursing services, rental of medical equipment, provision of telemedicine consultations and onsite vaccination.

Revenue from Managed Healthcare Solutions and GP Clinic Services recorded decline or similar levels of revenue due to lower patient volumes since the onset of the Covid-19 pandemic.

Revenue from Pharmaceutical services was on an uptrend since FY19 due to an increase in demand for medical supplies from local hospitals stocking up to anticipate any supply chain disruption (Figure 2).

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!